Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif.
| Revenue (Most Recent Fiscal Year) | $11.16M |
| Net Income (Most Recent Fiscal Year) | $-148.12M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 20.54 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.24 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1194.05% |
| Net Margin (Trailing 12 Months) | -1189.14% |
| Return on Equity (Trailing 12 Months) | -84.17% |
| Return on Assets (Trailing 12 Months) | -60.51% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.22 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.31 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.26 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.36 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.42 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 99.18M |
| Free Float | 90.71M |
| Market Capitalization | $230.10M |
| Average Volume (Last 20 Days) | 1.74M |
| Beta (Past 60 Months) | 2.33 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.54% |
| Percentage Held By Institutions (Latest 13F Reports) | 77.51% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |